Grace Therapeutics (GRCE) Cash from Investing Activities (2019 - 2024)

Grace Therapeutics has reported Cash from Investing Activities for 6 years, with the latest figure at $15000.0 in Q4 2024.

• Quarterly Cash from Investing Activities rose 100.23% year-over-year to $15000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $15000.0 (up 171.43% YoY) and the FY2024 annual result came in at $104000.0, down 99.21% from the prior year.
• Cash from Investing Activities rose to $15000.0 in Q4 2024 per GRCE's latest filing, from -$15000.0 in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $13.3 million in Q2 2022 and troughed at -$8.4 million in Q1 2021.
• A 5-year average of $445277.8 and a median of -$2000.0 in 2022 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2021 and 2023: Cash from Investing Activities plunged 19141.67% in 2021, then jumped 45281.82% in 2023.
• Over 5 years, Cash from Investing Activities stood at -$1.4 million in 2020, then soared by 140.6% to $557000.0 in 2021, then plunged by 997.85% to -$5.0 million in 2022, then plunged by 31.05% to -$6.6 million in 2023, then surged by 100.23% to $15000.0 in 2024.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $15000.0, -$15000.0, and $6.5 million for Q4 2024, Q2 2024, and Q1 2024 respectively.